One Way to Lower Drug Costs: Price Drugs by Indication (Guest: Roger Klein)
Rather than government mandated price controls on drugs, why not have drug companies base prices on indication? Roger D. Klein discusses “indication specific” drug prices and how this might lower prices and improve health outcomes.
Dr. Klein has advised the FDA, HHS and CMS and discusses how drugs are currently priced, why the current system is inefficient, how indication specific pricing works, what “disease specific” rebates are and how they would work, whether such an idea could work in today’s regulatory climate, the challenges and the opportunities. More of Roger D. Klein’s work can be seen at http://rogerdklein.com